Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;67(7):e28409.
doi: 10.1002/pbc.28409. Epub 2020 May 13.

The COVID-19 Pandemic: A Rapid Global Response for Children With Cancer From SIOP, COG, SIOP-E, SIOP-PODC, IPSO, PROS, CCI, and St Jude Global

Affiliations
Free PMC article

The COVID-19 Pandemic: A Rapid Global Response for Children With Cancer From SIOP, COG, SIOP-E, SIOP-PODC, IPSO, PROS, CCI, and St Jude Global

Michael Sullivan et al. Pediatr Blood Cancer. .
Free PMC article

Abstract

The COVID-19 pandemic is one of the most serious global challenges to delivering affordable and equitable treatment to children with cancer we have witnessed in the last few decades. This Special Report aims to summarize general principles for continuing multidisciplinary care during the SARS-CoV-2 (COVID-19) pandemic. With contributions from the leadership of the International Society for Pediatric Oncology (SIOP), Children's Oncology Group (COG), St Jude Global program, and Childhood Cancer International, we have sought to provide a framework for healthcare teams caring for children with cancer during the pandemic. We anticipate the burden will fall particularly heavily on children, their families, and cancer services in low- and middle-income countries. Therefore, we have brought together the relevant clinical leads from SIOP Europe, COG, and SIOP-PODC (Pediatric Oncology in Developing Countries) to focus on the six most curable cancers that are part of the WHO Global Initiative in Childhood Cancer. We provide some practical advice for adapting diagnostic and treatment protocols for children with cancer during the pandemic, the measures taken to contain it (e.g., extreme social distancing), and how to prepare for the anticipated recovery period.

Keywords: Burkitt lymphoma; COVID-19; Hodgkin lymphoma; SARS-CoV-2; WHO Global Initiative on Childhood Cancer; Wilms tumor; acute lymphoblastic leukemia; childhood cancer; low-grade glioma; nephroblastoma; pediatrics; retinoblastoma.

Conflict of interest statement

The authors declare no conflicts of interest.

Similar articles

See all similar articles

References

    1. Lam CG, Howard SC, Bouffet E, Pritchard‐Jones K. Science and health for all children with cancer. Science. 2019;363(6432):1182‐1186. - PubMed
    1. Bhakta N, Force LM, Allemani C, et al. Childhood cancer burden: a review of global estimates. Lancet Oncol. 2019;20(1):e42‐e53. - PubMed
    1. Howard SC, Davidson A, Luna‐Fineman S, et al. A framework to develop adapted treatment regimens to manage pediatric cancer in low‐ and middle‐income countries: the Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP). Pediatr Blood Cancer. 2018;64(S5):e26879.
    1. Hesseling P, Israels T, Harif M, Chantada G, Molyneux E. Pediatric oncology in developing countries. Practical recommendations for the management of children with endemic Burkitt lymphoma (BL) in a resource limited setting. Pediatr Blood Cancer. 2013;60(3):357‐362. - PubMed
    1. Hunger SP, Sung L, Howard SC. Treatment strategies and regimens of graduated intensity for childhood acute lymphoblastic leukemia in low‐income countries: a proposal. Pediatr Blood Cancer. 2009;52(5):559‐565. - PubMed
Feedback